- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06716242
Validierung des MaiRa-Präeklampsietests zum Screening auf frühe/späte Präeklampsie im ersten und zweiten Trimester (iPregnostic)
Prospektive, beobachtende, multizentrische Studie zur Bestätigung der Leistung des molekularen Screenings zur Früherkennung von Präeklampsie
Preeclampsia (PE) is a major obstetric complication with severe short- and long-term consequences for both mother and fetus. Early detection is critical to mitigate PE-related morbidity and mortality. Effective screening tools are needed to identify women at risk, enabling timely preventive and therapeutic interventions.
Current screening methods primarily target placental biomarkers like sFLT1 and PlGF, which are limited to short-term predictions near symptom onset. Existing first-trimester assessments that incorporate maternal factors and Doppler metrics remain constrained by low sensitivity (<41%) in compliance with NICE and ACOG guidelines.
Recent advancements in cell free RNA (cf-RNA) analysis have revealed potential in first-trimester PE prediction. Findings from the PREMOM study (NCT04990141) established a molecular profile for early-onset preeclampsia (EOPE) and late-onset preeclampsia (LOPE) through cfRNA analysis, culminating in the development of the MaiRa Preeclampsia Test (Maternal Advanced and Innovative Preeclampsia Risk Assessment), which demonstrated high predictive performance for first- and second-trimester screening.
The current study hypothesizes that the MaiRa Preeclampsia Test is generalizable, maintaining its predictive accuracy in an independent cohort.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This multicentre, prospective observational study aims to validate the MaiRa Preeclampsia Test, a molecular screening tool for predicting early-onset preeclampsia (EOPE) and late-onset preeclampsia (LOPE) in the first and second trimesters of pregnancy. The study will evaluate its diagnostic accuracy, including sensitivity, specificity, predictive values, and area under the curve (AUC).
Study Design:
Duration: 40 months
- Recruitment and Sample Collection: 28 months
- Sample Analysis: 32 months
- Follow-Up: 8 months
- Statistical Analysis and Publication: 6 months Participants: 7,473 pregnant women from 12 tertiary hospitals in Spain.
Visits:
- Visit 1 (T1): 9-14 weeks' gestation (first blood sample)
- Visit 2 (T2): 15-26 weeks' gestation (second blood sample)
- Visit 3 (T3): ≥27 weeks' gestation (third blood sample)
Blood samples will be analyzed using the MaiRa Preeclampsia Test, with results correlated against obstetric outcomes as the gold standard. Data will be documented in an electronic Case Report Form (eCRF). Quality assurance will be maintained via continuous data monitoring and verification.
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienorte
-
-
Alicante
-
Alicante, Alicante, Spanien, 03010
- Hospital General Universitario Dr. Balmis
-
-
Barcelona
-
Barcelona, Barcelona, Spanien, 08025
- Hospital de la Santa Creu i Sant Pau
-
-
Castellón
-
Vinaròs, Castellón, Spanien, 12500
- Hospital Comarcal de Vinaròs
-
-
Cádiz
-
Cadiz, Cádiz, Spanien, 11009
- Hospital Universitario Puerta del Mar
-
-
La Coruña
-
A Coruña, La Coruña, Spanien, 15006
- Hospital Universitario A Coruña
-
-
Madrid
-
Torrejón de Ardoz, Madrid, Spanien, 28850
- Hospital Universitario de Torrejón
-
-
Murcia
-
El Palmar, Murcia, Spanien, 30120
- Hospital Clínico Universitario Virgen de la Arrixaca
-
-
Santa Cruz de Tenerife
-
San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spanien, 38320
- Hospital Universitario de Canarias
-
-
Valencia
-
Manises, Valencia, Spanien, 46940
- Hospital de Manises
-
Valencia, Valencia, Spanien, 46017
- Hospital Universitario Doctor Peset
-
Valencia, Valencia, Spanien, 46026
- Hospital Universitario y Politécnico La Fe
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Pregnant patients aged 18 years or older, recruited between 9 and 14 weeks' gestation during routine obstetrical follow-ups at referral hospitals.
Beschreibung
Inclusion Criteria:
- Signed informed consent approved by the Ethics Committee.
- Women ≥18 years of age at consent.
- Single gestation pregnancies with first sample collection (T1) possible between 9 and 14 weeks' gestation.
Exclusion Criteria:
- Active neoplasm.
- History of organ or bone marrow transplantation.
- Maternal transfusion within 8 weeks before sample collection.
- Evidence of early pregnancy loss at consent.
- Severe, uncontrolled infections.
- Other investigator-assessed risks that could compromise participation or data quality.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Pregnant patients aged 18 years or older
Pregnant patients aged 18 years or older recruited between 9 and 14 weeks' gestation during routine obstetrical follow-ups at referral hospitals. |
Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data will also be compiled. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Validation of the MaiRa Preeclampsia Test for first-trimester screening (9-14 weeks) of EOPE
Zeitfenster: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
Sensitivity, specificity, accuracy, F1-score, positive/negative predictive values, false discovery rate, AUC. |
From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Validation of second-trimester screening (15-26 weeks) for EOPE
Zeitfenster: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
Sensitivity, specificity, accuracy, F1-score, positive/negative predictive values, false discovery rate, AUC. |
From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
|
Validation of second-trimester screening (15-26 weeks) for LOPE
Zeitfenster: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
Sensitivity, specificity, accuracy, F1-score, positive/negative predictive values, false discovery rate, AUC. |
From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Exploratory outcome: Validation of first-trimester screening (9-14 weeks) for LOPE
Zeitfenster: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
Sensitivity, specificity, accuracy, F1-score, positive/negative predictive values, false discovery rate, AUC. |
From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
|
Exploratory outcome: Validation of first and second trimester screening for other pregnancy complications
Zeitfenster: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
Other pregnancy complications such as preterm labour, intrauterine growth restriction, gestational diabetes and placenta previa among others. Sensitivity, specificity, accuracy, F1-score, positive/negative predictive values, false discovery rate, AUC. |
From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
|
Exploratory outcome: Molecular characterization of cfRNA and other biomarkers across gestation
Zeitfenster: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
DNA/RNA/proteins/metabolites associated with gestational age and clinical outcomes. |
From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
|
Exploratory outcome: Identification of candidate biomarkers in maternal blood for therapeutic interventions
Zeitfenster: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
Molecular characterization (DNA/RNA/proteins/metabolites). |
From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Carlos Simón, MD, PhD, Carlos Simon Foundation
- Hauptermittler: Tamara Garrido, PhD, iPremom
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- IPR-IPR-TG-24-01
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .